BACKGROUND: Transsphenoidal surgery (TSS) is the treatment of choice for Cushing's disease (CD). Postoperative hypercortisolemia mandates further therapy. OBJECTIVE: The aim of the study was to characterize patients without immediate postoperative remission who have a delayed decrease to normal or low cortisol levels without further therapy. DESIGN AND SETTING: A retrospective case series was conducted at three tertiary care centers. PATIENTS AND INTERVENTION: We reviewed the records of 620 patients (512 females, 108 males; mean age, 38 +/- 13 yr) who underwent transsphenoidal pituitary surgery for CD between 1982 and 2007. RESULTS: Outcomes were classified into the following three groups based upon the postoperative pattern of cortisol testing: group IC (immediate control) included 437 of the 620 patients (70.5%) with hypocortisolism and/or cortisol normalization throughout the postoperative follow-up; group NC (no control) included 148 of 620 patients (23.9%) with persistent hypercortisolism; and group DC (delayed control) included 35 of 620 patients (5.6%) who had early elevated or normal UFC levels and developed a delayed and persistent cortisol decrease after an average of 38 +/- 50 postoperative days. The total rate of recurrence was 13% at a median follow-up time of 66 months after TSS; the cumulative rate of recurrence at 4.5 yr was significantly higher in group DC vs. group IC (43 vs. 14%; P = 0.02). CONCLUSIONS: Hormonal assessment in the immediate postoperative period after TSS for CD may be misleading because delayed remission can occur in a subset of patients. Expectant management and retesting may spare some patients from unnecessary further treatment. Optimal timing to determine the need for further therapy after TSS remains to be determined.
BACKGROUND: Transsphenoidal surgery (TSS) is the treatment of choice for Cushing's disease (CD). Postoperative hypercortisolemia mandates further therapy. OBJECTIVE: The aim of the study was to characterize patients without immediate postoperative remission who have a delayed decrease to normal or low cortisol levels without further therapy. DESIGN AND SETTING: A retrospective case series was conducted at three tertiary care centers. PATIENTS AND INTERVENTION: We reviewed the records of 620 patients (512 females, 108 males; mean age, 38 +/- 13 yr) who underwent transsphenoidal pituitary surgery for CD between 1982 and 2007. RESULTS: Outcomes were classified into the following three groups based upon the postoperative pattern of cortisol testing: group IC (immediate control) included 437 of the 620 patients (70.5%) with hypocortisolism and/or cortisol normalization throughout the postoperative follow-up; group NC (no control) included 148 of 620 patients (23.9%) with persistent hypercortisolism; and group DC (delayed control) included 35 of 620 patients (5.6%) who had early elevated or normal UFC levels and developed a delayed and persistent cortisol decrease after an average of 38 +/- 50 postoperative days. The total rate of recurrence was 13% at a median follow-up time of 66 months after TSS; the cumulative rate of recurrence at 4.5 yr was significantly higher in group DC vs. group IC (43 vs. 14%; P = 0.02). CONCLUSIONS: Hormonal assessment in the immediate postoperative period after TSS for CD may be misleading because delayed remission can occur in a subset of patients. Expectant management and retesting may spare some patients from unnecessary further treatment. Optimal timing to determine the need for further therapy after TSS remains to be determined.
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: Bernd Markus Hofmann; Michal Hlavac; Ramon Martinez; Michael Buchfelder; Otto Albrecht Müller; Rudolf Fahlbusch Journal: J Neurosurg Date: 2008-01 Impact factor: 5.115
Authors: Manish K Aghi; Josh Petit; Paul Chapman; Jay Loeffler; Anne Klibanski; Beverly M K Biller; Brooke Swearingen Journal: Clin Neurosurg Date: 2008
Authors: B Swearingen; B M Biller; F G Barker; L Katznelson; S Grinspoon; A Klibanski; N T Zervas Journal: Ann Intern Med Date: 1999-05-18 Impact factor: 25.391
Authors: A Brew Atkinson; Adele Kennedy; M Ivan Wiggam; David R McCance; Brian Sheridan Journal: Clin Endocrinol (Oxf) Date: 2005-11 Impact factor: 3.478
Authors: Joshua H Petit; Beverly M K Biller; Torunn I Yock; Brooke Swearingen; John J Coen; Paul Chapman; Marek Ancukiewicz; Marc Bussiere; Anne Klibanski; Jay S Loeffler Journal: J Clin Endocrinol Metab Date: 2007-11-20 Impact factor: 5.958
Authors: B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro Journal: J Clin Endocrinol Metab Date: 2008-04-15 Impact factor: 5.958
Authors: Chirag G Patil; Daniel M Prevedello; Shivanand P Lad; Mary Lee Vance; Michael O Thorner; Laurence Katznelson; Edward R Laws Journal: J Clin Endocrinol Metab Date: 2007-12-04 Impact factor: 5.958
Authors: Philip C Johnston; Laurence Kennedy; Amir H Hamrahian; Zahrae Sandouk; James Bena; Betul Hatipoglu; Robert J Weil Journal: Pituitary Date: 2017-08 Impact factor: 4.107
Authors: Luis G Perez-Rivas; Marily Theodoropoulou; Francesco Ferraù; Clara Nusser; Kohei Kawaguchi; Constantine A Stratakis; Fabio Rueda Faucz; Luiz E Wildemberg; Guillaume Assié; Rudi Beschorner; Christina Dimopoulou; Michael Buchfelder; Vera Popovic; Christina M Berr; Miklós Tóth; Arif Ibrahim Ardisasmita; Jürgen Honegger; Jerôme Bertherat; Monica R Gadelha; Felix Beuschlein; Günter Stalla; Masayuki Komada; Márta Korbonits; Martin Reincke Journal: J Clin Endocrinol Metab Date: 2015-05-05 Impact factor: 5.958
Authors: Nadia Hameed; Chris G Yedinak; Jessica Brzana; Sakir H Gultekin; Nicholas D Coppa; Aclan Dogan; Johnny B Delashaw; Maria Fleseriu Journal: Pituitary Date: 2013-12 Impact factor: 4.107
Authors: Hai Sun; Chris Yedinak; Alp Ozpinar; Jim Anderson; Aclan Dogan; Johnny Delashaw; Maria Fleseriu Journal: J Neurol Surg B Skull Base Date: 2015-01-21
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958
Authors: G Aranda; J Enseñat; M Mora; M Puig-Domingo; M J Martínez de Osaba; G Casals; E Verger; M T Ribalta; F A Hanzu; I Halperin Journal: Pituitary Date: 2015-02 Impact factor: 4.107